Chicago-based digital health company Sibel Health has successfully closed a Series C extension financing round, raising its total Series C funding to $39 million. This latest infusion includes strategic investments from Japanese pharmaceutical leader Maruho Co., Ltd. and innovation powerhouse Samsung Next, complementing the initial Series C round led by The Steele Foundation for Hope and significant participation from medical technology firm Dräger.
At the core of Sibel Health’s offering is the FDA-cleared ANNE® One platform, a suite of clinical-grade wearable sensors that continuously monitor vital signs and integrate seamlessly with mobile devices for real-time display and alerting. This technology supports the shift in healthcare from episodic, hospital-centered care to continuous, remote patient monitoring—a transition underscored by Samsung Next’s commitment to pairing Sibel’s medical wearables with their mobile ecosystem to deliver cost-effective, clinically validated solutions.
Steve Xu, MD, CEO of Sibel Health, highlights the strategic value of the new investors: “These partners bring more than capital — they bring expertise, scale, and reach to help us expand our clinical-grade medical wearables and AI-driven algorithms. Our collaboration with Maruho enhances our dermatology digital health initiatives, while Samsung Next amplifies our global technology footprint.” Akihiko Ikoma MD PhD, Senior Medical Director at Maruho, adds, “We are co-developing future digital health breakthroughs focused initially on skin conditions such as itch, marking a critical expansion of digital therapeutics in dermatology.”
The company also announced key board appointments to steer its growth trajectory. Kimberly Querrey, Chair and CEO of Gulf Shore Private Capital and a trustee at Northwestern University, has been elected Chairwoman of Sibel Health’s board. Tim Sullivan, co-founder and Vice Chair of Madison Dearborn Partners and Chairman of Northwestern Memorial Healthcare Corporation, joined as an independent board member and investor. Their combined expertise in healthcare innovation, governance, and commercialization is expected to accelerate Sibel Health’s ambitions to integrate continuous real-world health data into clinical trials and patient care.
Market Perspective and Industry Outlook
Sibel Health’s trajectory reflects a broader healthcare trend: the fusion of wearable technology, AI analytics, and cloud platforms to revolutionize patient monitoring outside traditional clinical settings. The company’s success in attracting strategic partners like Maruho and Samsung Next signals increasing confidence in the clinical and commercial viability of advanced wearables, particularly in managing chronic conditions and enhancing clinical trial data fidelity.
The dermatology focus, propelled by Maruho’s pharmaceutical heritage, is especially noteworthy. Digital health’s intersection with specialty areas such as dermatology, historically underserved by remote monitoring tools, opens new frontiers for personalized treatment and real-world evidence collection.
Looking ahead, Sibel Health stands to capitalize on a growing global market demand for continuous, predictive clinical intelligence. The integration of AI-driven insights with scalable wearable devices not only promises better patient outcomes but also streamlines clinical trial workflows, potentially shortening drug development timelines. If Sibel Health successfully leverages its deepening strategic alliances and robust funding, it could emerge as a pivotal player in defining the future of digital health monitoring.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
